Johnson & Johnson is proud to be recognized on the Women’s Business Enterprise National Council’s (WBENC) 16th annual list of America’s Top Corporations for Women’s Business Enterprises, which honors corporations whose supplier diversity programs excel at removing barriers and providing opportunity for growth to women-owned businesses.
WBENC is the nation’s leading third-party certifier of businesses owned and operated by women and is accepted by more than 1,000 of America’s most recognizable brands, including Johnson & Johnson. read more
Abbott Vascular has recalled the MitraClip Clip Delivery System due to an issue with the delivery system deployment process. Abbott Vascular has received reports of cases where the Clip Delivery System could not be detached from the Clip due to a malfunction of the device. These cases resulted in open heart surgery to retrieve the delivery system. Abbott Vascular is therefore recalling the MitraClip Delivery System to provide updated instructions and training for health care providers who use the device.
The use of affected products may cause serious adverse health consequences, including serious patient injury or death. Currently there are 3,534 devices on the market, with nine reports of this malfunction. There has been 1 death.
BioInvent is granted a patent in Europe for the immune-oncology antibody BI-505
BioInvent International (BINV) announces today that the European Patent Office, EPO, has decided to grant the company’s patent EP 1 960 432, relating to the immune-oncology antibody BI-505. BioInvent plans to shortly initiate a Phase II trial with BI-505 in patients with multiple myeloma, with the aim to prevent or significantly delay relapse of this serious form of hematologic cancer. More information is available at www.bioinvent.com.
Nephros Launches SSUmini and Provides S100 Update
.–(BUSINESS WIRE)–Nephros, Inc. (OTCQB:NEPH) (the “Company”), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration (“HDF”) system for use with a hemodialysis machine for the treatment of patients with end stage renal disease, announces the release of the SSUmini, a smaller version of its SSU-D medical device. read more
Provectus Biopharmaceuticals Amends Protocol for Phase 3 Study of PV-10 in Treatment of Locally Advanced Cutaneous Melanoma
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company (“Provectus” or “The Company”), today announced that the protocol for its phase 3 clinical trial for PV-10 as an investigational treatment for melanoma has been amended to reflect current and evolving standards of care and applicable patient population for a global study in melanoma. read more
Allied-Bristol Life Sciences Launches iβeCa Therapeutics from NYU School of Medicine to Develop Novel Cancer Therapeutics Targeting the Wnt Pathway
BOSTON–(BUSINESS WIRE)–Allied-Bristol Life Sciences, LLC (ABLS), a biopharmaceutical enterprise jointly owned between Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY), announced that it has launched a new subsidiary, iβeCa Therapeutics, to license proprietary compounds from NYU School of Medicine that target the Wnt signalling pathway. The Wnt pathway plays a key role in the development and progression of a number of cancers affecting large numbers of patients. iβeCa Therapeutics will focus on further discovery and development activities needed to identify candidates for human clinical testing. read more
Takeda and Frazier Healthcare Partners Launch Outpost Medicine to Develop New Therapeutics in Urology and Gynecology
OSAKA, Japan & MENLO PARK, Calif.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TOKYO:4502) and Frazier Healthcare Partners today announced the formation of Outpost Medicine, a biopharmaceutical company focused on the development of new treatments of urologic and gynecologic diseases and disorders. read more
ERYTECH Receives USPTO Notice of Allowance for Patent Covering ERYCAPS Immunotherapy Technology
ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 – ERYP), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 12/672,094 entitled “Composition and Therapeutic Anti-tumor Vaccine.” read more
New Data Show That Veracyte’s Afirma® Gene Expression Classifier Reduces Unnecessary Thyroid Surgeries and Costs During Long-Term Follow-Up
PRNewswire/ — Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced publication of data demonstrating that the Afirma Gene Expression Classifier (GEC) reduces unnecessary surgeries in thyroid cancer diagnosis during long-term clinical follow-up. The study is the first to use a national healthcare claims database to determine the real-world impact of the genomic test on patient care and to quantify the costs associated with thyroid surgery. The findings appear online in the journal Current Medical Research & Opinion. read more
QIAGEN Partners With Taiwan in Nationwide TB Screening Effort
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Gold, the modern standard for accuracy in diagnosing latent tuberculosis (TB) infection, was selected by the Taiwan Centers for Disease Control (Taiwan CDC) to replace the tuberculin skin test for screening at-risk individuals five years and older.
Starting this month, Taiwan’s nationwide TB control effort will use QuantiFERON-TB Gold to test close contacts of patients with active tuberculosis, a contagious and life-threatening disease. In addition to treating patients with active TB, Taiwan will provide antibiotic treatment for patients identified as having latent TB infection (which if untreated can remain dormant and be activated years later). Only children younger than five years of age will be screened with the skin test.